期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Changes in Bone Mineral Density through 96 Weeks in Antiretroviral-Naïve HIV-1 Infected Patients Receiving Abacavir/Lamivudine and Raltegravir in the SHIELD Trial
1
作者 linda battalora Amy Thomas +2 位作者 Brian Wine Belinda Ha Benjamin Young 《World Journal of AIDS》 2014年第1期38-44,共7页
Decreased bone mineral density (BMD) and osteoporotic fractures are areas of increasing concern among HIV-infected persons. Particular concern is the rapid decline in BMD after initiation of antiretroviral treatment (... Decreased bone mineral density (BMD) and osteoporotic fractures are areas of increasing concern among HIV-infected persons. Particular concern is the rapid decline in BMD after initiation of antiretroviral treatment (ART). This report describes DEXA-assessed changes in BMD and body fat in a study of fifteen antiretroviral-na?ve adults initiating abacavir/lamivudine and raltegravir for 96 weeks. Median percent changes from baseline at weeks 48 and 96 in BMD were 0.29% and -0.11% (spine);-1.25% and -1.75% (left hip). Median percent changes from baseline in fat from baseline were -0.82% and -3.04% (trunk);2.12% and 2.01% (limb). In this pilot study, ABC/3TC + RAL treatment had limited impact on BMD and body fat. 展开更多
关键词 Bonedensity ABACAVIR HIV INTEGRASE LAMIVUDINE RALTEGRAVIR
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部